Medical News

RSS

Cabazitaxel offers added benefit for men with metastatic prostate cancer

Cabazitaxel has been approved since March 2011 in men with metastatic prostate cancer who no longer respond to conventional therapy with hormone blockers and have already been pre-treated with the cytostatic drug docetaxel.

30 May 2012

DFG to establish 20 CRCs by 1 July 2012

The Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) is to establish 20 Collaborative Research Centres (CRCs) by 1 July 2012. This decision was taken by the Grants Committee at its spring session in Bonn. The new CRCs will receive funding totalling 176 million euros (including a 20 percent programme allowance for indirect project costs) for the initial 4-year funding period.

30 May 2012

PRS launches Global Regulatory Intelligence Database

Pharmaceutical Regulatory Services, Inc., a global provider of regulatory and pharmacovigilance support to the pharmaceutical, biotechnology and medical device industries, is pleased to announce the launch of GRID - Global Regulatory Intelligence Database.

30 May 2012

ASCs promising source of cells for use in plastic surgery and regenerative medicine

Adipose stem cells (ASCs)—stem cells derived from fat—are a promising source of cells for use in plastic surgery and regenerative medicine, according to a special review in the June issue of Plastic and Reconstructive Surgery, the official medical journal of the American Society of Plastic Surgeons.

30 May 2012

CRI relaunches Cancer Immunity journal

The Cancer Research Institute, Inc. (CRI), a U.S. nonprofit organization established in 1953 to advance the discovery and development of safe and effective immunotherapies for cancer, today announced the relaunch of the open access, online journal Cancer Immunity, the official journal of the Cancer Research Institute.

30 May 2012

MD Bioproducts launches new subtype specific antibody as marker for AS

MD Bioproducts launches a new subtype specific antibody as a marker for ankylosing spondylitis (AS): HLA-B*2705. The anti-HLA-B*2705 antibody, clone MARB4, has been validated for use in flow cytometry, tissue staining and immunoprecipitation.

30 May 2012

Positive results from RedHill’s RHB-103 bioequivalence trial on acute migraine

RedHill Biopharma Ltd., an emerging Israeli biopharmaceutical company focusing primarily on development of late clinical-stage (Phase II/III), patent protected, new formulations and combinations of existing drugs, announces positive results in a pivotal bioequivalence clinical trial with RHB-103, an oral thin-film formulation of Rizatriptan for the treatment of acute migraine.

30 May 2012

Researchers develop STeleR post-stroke rehabilitation program

Researchers led by Regenstrief Institute investigator Neale Chumbler, Ph.D., a research scientist with the Center of Excellence on Implementing Evidence-Based Practice at the Richard Roudebush VA Medical Center in Indianapolis, have developed STeleR, a home telerehabilitation program that they report improves lower body physical functioning after a stroke.

30 May 2012

Widespread cholera vaccination needed in Haiti while improvements made to water, sanitation systems

"As the world's worst outbreak of cholera continues to ravage Haiti, international donors have averted their gaze," a Washington Post editorial writes. The editorial notes that a "pilot project to vaccinate Haitians against the disease ... reached only one percent of the population, with no immediate prospect of expansion," and "of the 100 or so cholera treatment centers that sprang up around the country after the disease was detected 19 months ago, fewer than a third remain."

30 May 2012

Bananas have healthier blend of sugars than sports drinks

Bananas have long been a favorite source of energy for endurance and recreational athletes. Bananas are a rich source of potassium and other nutrients, and are easy for cyclists, runners or hikers to carry.

30 May 2012

Marshall Edwards initiates ME-344 Phase I trial in solid tumors

Marshall Edwards, Inc., an oncology company focused on the clinical development of novel therapeutics targeting cancer metabolism, announced today that the first cohort of patients has been dosed in a Phase I clinical trial of ME-344, the Company's lead mitochondrial inhibitor drug candidate, in patients with refractory solid tumors.

30 May 2012

iView Systems announces availability of iTrak version 5.5

iView Systems, a leading provider of loss prevention solutions for the security and surveillance environment, today announced the availability of its latest version of iTrak, the award winning Incident Reporting & Risk Management platform.

30 May 2012

Scientists identify 20 distinct gene mutations in patients with FGD

A rare disease which often first presents in newborn babies has been traced to a novel genetic defect, scientists at Queen Mary, University of London have found.

30 May 2012

Officials at WHA fail to agree on convention to encourage R&D into health issues in developing countries

Health officials attending last week's World Health Assembly "failed to come to an agreement on a binding convention on stimulating research and development [R&D] focusing on the health problems of developing countries," BMJ reports.

30 May 2012

NanoBio-Europe conference to take place from June 18-20 in Varese

The 8th NanoBio-Europe conference will take place on 18 - 20 June 2012 in Varese (Lombardy, Northern Italy), showcasing the latest international developments in nanobiotechnology, and providing a platform to facilitate interdisciplinary communications, new collaborations for delegates from academic, industrial and clinical backgrounds.

30 May 2012

PKCZ protein could serve as new treatment target for prostate cancer

A newly-discovered protein found only in prostate cancer cells could be used as a marker of the disease and offer a new treatment target, according to a study in the British Journal of Cancer.

30 May 2012

Scientists develop synthetic peptide that overcomes cancer cells’ survival defenses

Scientists at the Dana-Farber/Children's Hospital Cancer Center have developed an anti-cancer peptide that overcomes the stubborn resistance to chemotherapy and radiation often encountered in certain blood cancers when the disease recurs following initial treatment.

30 May 2012